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A B S T R A C T
The Institute of Public Health of the Osijek-Baranja County has processed the data on cancer patients that were col-
lected from mandatory county hospitals data reports, county bureaus of statistics and the County Register of Deaths. The
cancers were defined according the International Statistical Classification of Diseases and Related Health Problems,
10th Revision (ICD-10), codes of malignant neoplasms (C00-C97), in situ neoplasms (D00-D09) and neoplasms of uncer-
tain or unknown behaviour (D37-D48). The aim of this article was to show the size of the cancer problem in Osijek-
-Baranja County (OBC) according to the all ICD-10 cancer groups. The cancer incidence and mortality estimated in pe-
riod 2001–2006 were prepared for all cancers based on gender and for age groups 0–19, 20–44, 45–64, 65+ by the year of
the first diagnosis of cancer. The median age at cancer diagnosis was 62.7 years, 61.2 years for females and 64.1 years for
males. Applying the EU age-standardized rate, the average annual incidence and mortality rates in the OBC were 411.6/
100,000 and 240.7/100,000, respectively. The incidence rates in both genders were highest for neoplasms of digestive or-
gans (C15-C26), respiratory and intrathoracic organs (C30-C39) and for breast (C50) (101.1, 63.6 and 44.3/100,000, re-
spectively). The first two groups of cancer in both genders were also the leading groups of cancer in males (141.6 and
124.9/100,000). The third position in males belonged to neoplasms of male’s genital organs (C60-C63, 58/100,000). The
leading group in females was C50 (79.3/100,000), followed by groups C15-C26 (73.2/100,000) and in situ neoplasms
(D00-D09) (51.4/100,000). The course and shape of mortality rate in the whole corresponded to the incidence rate, but at
the lower level. The only exception referred to group C15-C26 (56.8/100,000) as leading mortality cancer group in fe-
males. The overall 5-year relative survival was 40.1%. Considering females, this rate amounted to 48.8% while this fig-
ure was much lower in men – 32.4%. In age group 65+, 52.6% of cancer patients developed a cancer and 65.4% of pa-
tients died at the same age. These basic parameters indicate that the OBC must put great efforts in creating a long-term
strategy for cancer prevention and early diagnostics in order to prolong life and improve the quality of life of cancer pa-
tients and raise the proportion of 5-year survival.
Key words: cancer, age-standardized mortality rate, age-standardized incidence rate, 5-year relative survival, age
distribution, median age, C00-D48, Croatia, Osijek-Baranja County
Introduction
The Europe Against Cancer programme was estab-
lished in the 1980s due to concerns of increasing cancer
incidence and death rates. The main areas of its activity
focussed on prevention, tobacco control (as one of the
most important risks), screening, education and train-
ing1. The success of such a preventive and basically
long-term programme should not be assessed within a
short period of time. Although in the period 1985–2000,
the results did not meet the expectations, the durability
and quality of the program has to demonstrate positive
results, despite the aging population. In 2012, it came to
an increase in the mortality from lung in females and
from pancreatic cancer in both genders, whiles the mor-
tality rate from all other cancers decreased2. The in-
creased in cancer incidence in the EU from 2004 to 2006
indicates that the cancers in the EU remains a major
public health problem requiring strong measures, partic-
ularly primary prevention3–5. Despite the aging popula-
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tion in the EU and an increased incidence of cancers in
an older age, it is expected that until the year 2020, the
EU will have managed to raise the survival and reduce
the mortality6,7. The most common cancer sites are lung,
breast and colorectal cancer. Given the prognosis, pan-
creatic cancer and lung cancer, followed by cancer of the
stomach and liver, will be the leading diagnoses in can-
cer’s mortality8,9. In the last 10 years, total incidence and
mortality cancer rates have been falling continuously in
the USA10. Certainly, better prevention and treatment
produce positive financial effects, especially if the future
trend of population aging is taken into consideration11.
Compared with other European countries, Croatia and
OBC holds a high and unfavourable position in cancer
morbidity and mortality12. In the OBC, several studies
were conducted (regarding to the some cancer sites or
even cancer groups), but there was not a single research
that encompasses all cancer groups13-15.
The aim of this article is to provide general informa-
tion on cancer in the OBC using the ICD-10. General in-
formation about cancer in Croatia has so far existed only
at the state level whereas at the county level, such infor-
mation was mostly unavailable.
Materials and Methods
Data source
Although the representativeness of their data might
be challenged, mandatory county hospitals data reports,
county bureaus of statistics and the County Register of
Deaths still represent the only available source of infor-
mation on the profile of cancer in the OBC. All data from
the 2001–2006 period originate from these institutions.
The cohort studied in this article included all people with
cancer who were registered as the patients in one of two
hospitals in OBC in the time period from 2001 to 2006
(follow up period from 1996 to 2010). Based on these
sources, a database of people who were hospitalized in
the area of the OBC for any reason whatsoever (includ-
ing cancer) has been generated16,17. The data on each of
the hospitalized patients have been supplemented with
data obtained from the Register of Deaths.
Data on every person with cancer are accompanied
with their chronological order of illness and hospitaliza-
tion. The database involved all hospitalizations and all
data on ONKO or BSL forms (mandatory statistical pat-
terns for all hospitalized patients in Croatia). The ONKO
form is mandatory statistical reports on every hospital-
ized cancer patients in Croatia. The BSL form is a man-
datory statistical report on every hospitalized person, re-
gardless of the causes of hospitalization. All cancer
patients coming from this area are hospitalized in state-
-owned (public) hospitals since there are still the only
hospitals here.
Statistical analysis
The cancers were classified according to the ICD-10
group of malignant neoplasms codes C00-D48. The can-
cer incidence and mortality estimates in the period from
2001 to 2006 were prepared for all cancers based on gen-
der and for age groups 0–19, 20–44, 45–64, 65+ by the
year at cancer diagnosis. Based on the 2001 census, the
analysis covered a total population of 330.506 people in
the OBC. The Croatian National Health Insurance is a
universal health insurance that covers all or almost all
costs treatment (depending on a personal choice of the
type of insurance) of Croatia citizens and provides them
with the same chances of recovery. Therefore, this article
can be said to comprise the entire population of cancer
patients treated in the OBC.
Descriptive statistics were used for both age and gen-
der. The survival rates reflect the outcome up to 5 years
after diagnosis for cancer patients who were diagnosed
during the period 2001–2005 and who have been followed
up for ³5 years, to the end of 2010. All survival estimates
were age-adjusted on the basis of four age groups. The
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Fig. 1. The median age of cancer patients at diagnosis and at
death by primary cancer site (C00-D48) and difference in years
between median age at death and at diagnosis in the OBC, peri-
ods 2001-2006. The rising trendlines in males suggests that a
very strong and extremely dependable relationship exist between
the median age at diagnosis and years, R2=0.924 (R2>0.80) and
strong relationship between median age at death and years, R2=
0.697 (R2>0.48<0.81). The rising trendlines in females suggests
that a weak relationship (if a relationship even exists) exists be-
tween the median age at diagnosis and years, R2=0.121 (R2>
0.04<0.16) and no relationship between median age at death
and years, R2=0.007 (R2>0.00<0.03).
analyses were conducted using age-specific rates, the
age-standardization-direct method and 95% confidence
intervals (95% CI). The standardized incidence and mor-
tality ratios as well as the 95% confidence intervals were
computed for C00-D48 pursuant to the year at cancer di-
agnosis. Also, both ratios were stratified according to the
year at cancer diagnosis, age and gender and adjusted to
fit into two 3-years time periods (2001–2003 and 2004–
2006). The median age is the observation ranked in the
middle; that is 50% of patients are diagnosed at an older
age and 50% are diagnosed at a younger age compared to
the median. The EU standard population was used in the
analysis18. The length of stay was determined according
to the date of admission and to the date of discharge with
regard to the index admission. The SAS statistical pack-
age (version 9.1, SAS Institute INC., Cary, NC, SAD) was
used for the statistical analysis19 and Microsoft® Office
Excel® 2007.
Results
According to the 2001 census, the analysis covered a
total population of 330.506 people in the OBC. From
2001 to 2006, a total of 9,532 people were registered with
cancer and treated at the two hospitals in the OBC. The
observation period was divided into two three-year peri-
ods, the first one comprises the 2001–2003 period and
the second one the 2004–2006.
The mean incidence of new cancers over the 6-year
study period (2001–2006) amounted to 1,589 cases/year,
equating to the OBC population age-standardized inci-
dence rate of 411.6/100,000 (SD±10.4, CI 391.2–432).
The incidence rate observed in the two periods decreased
in females (from 391.9/100,000, SD±14, CI 364.5–419.4
to 348.3/100,000, SD±13.2, CI 322.5–374), in both gen-
ders (from 420.6/100,000, SD±10.5, CI 340–441.3 to
402.6/100,000, SD±10.3, CI 382.5–422), while it went up
in males (from 484.6/100,000, SD±17.2, CI 451–518.3 to
503.8/100,000, SD±17.5, CI 469.5–538.1) (Table 1 and 3,
Figure 2). In the 2001–2006 period, the incidence rates in
males and females were 494.2/100,000 (SD±17.2, CI
451–518.3), and 370.1/100,000 (SD±17.5, CI 469.5–
538.1), respectively, which reveals the fact that the chan-
ces of males to be diagnosed with cancer were higher by
one third than the chances of females to go down with
the same illness in the same period.
In the 2001–2006 period, 968 patients died of cancer
on a yearly basis on average, which implies the mortality
rate of 240.7/100,000 (SD±7.8, CI 225.4–256). Regarding
both genders, the mortality rate fell from 256.1/100,000
(SD±8, CI 240.3–271.8) in the 2001–2003 period to
225.3/100,000 (SD±7.5, CI 210.5–240.1) in the 2004–
2006 period. In the same time periods the mortality rate
in males descended from 362.3/100,000 (SD±14.9, CI
333.2–391.4) to 341.6/100,000 (SD±14.4, CI 313.4–361).
Like the incidence rate, the mortality rate in females
continuously and uniformly decreased from 184/100,000
(SD±9, CI 166.3–201.6) to 147.4/100,000 (SD±8.1, CI
131.6–163.3).
The median age of patients at diagnosis of cancer was
62.7 years in period 2001–2006 (Table 2, Figure 1). The
difference in the median age at diagnosis of cancer be-
tween the two time periods was 1.32 years. The diagnosis
of cancer in a group of malignant neoplasms of bone and
articular cartilage (C40-C41) and malignant neoplasms
of thyroid and other endocrine glands (C73-C75) in the
second period shifted to the younger age by 9.57 and 1.78
years, respectively. Conversely, neoplasms of lip, oral cav-
ity and pharynx (C00-C14), malignant neoplasm of breast
(C50) and neoplasms of mesothelial and soft tissue (C45-
C49) shifted to an older age by 3.41, 4.41 and 4.98 years,
respectively.
The median age at diagnosis of cancer in females was
61.2 years in both periods with a shift to an older age at
diagnosis of cancer for 1.13 years in the second period.
The median age of malignant neoplasms of respiratory
and intrathoracic organs (C30-C39) and cancer groups
C15-C26 increased by 0.3 and 0.91 years in the second
period, while cancer groups C00-C14 and malignant neo-
plasm of eye, brain and other parts of central nervous
system (C69-C72) increased by 3.51 and 3.58, respec-
tively.
The median age at diagnosis of cancer in males was
64.1 years in both period with a shift to an older age at di-
agnosis of cancer for 1.29 years in the second period. The
biggest difference in the median age referred to in situ
neoplasms (D00-D09), with a shift to an older age in the
second period by 23.06 years.
The median age at death of cancer was 69.2 years.
More precisely, this figure was 67.7 years for men and
70.6 years for women. The difference in the median age
at death of cancer between the two periods was 0.34
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TABLE 1
HISTORICAL DATA ON THE OVERALL AGE-STANDARDIZED INCIDENCE AND MORTALITY RATE FROM ALL CANCERS PER 100,000




Males Females Both genders Males Females Both genders
N ASR N ASR N ASR N ASR N ASR N ASR
2001–2003 784 484.6 833 391.9 1,617 420.6 587 362.3 442 184.0 1,029 256.1
2004–2005 816 503.8 745 348.3 1,561 402.6 553 341.6 354 147.4 907 225.3
2001–2006 800 494.2 789 370.1 1,589 411.6 570 352.0 398 165.7 968 240.7
N – average number of cases per year, ASR – age-standardized rate (EU)



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































years and it resulted from the higher median age in the
second one. The highest median age at death of cancer in
males was detected in the groups of malignant neo-
plasms of male genital organs (C60-C63, 75 years) and
neoplasms of uncertain or unknown behaviour (D37-
D48, 73.7 years). With respect to females, the highest
median ages at death were found with cancer groups of
melanoma and other malignant neoplasms of skin (D43-
D44, 75.4 years), D37-D48 (74.9 years), malignant neo-
plasms of urinary tract (C64-C68, 73.4 years) and C00-
C14 (73 years).
In the period from 2001 to 2006, the OBC population
was felled by cancer at a rate of 411.6/100,000 (SD±12.6,
CI 539.6–589.1) with indications of a downward trend in
the second reference period. In the first period (2001–
2003), the incidence rate was higher than that in the sub-
sequent three-year period (420/100,000 and 408/100,000)
(Table 3, Figure 2). The patients were commonly diag-
nosed with malignant neoplasms of digestive organs
(C15-C26, 101.1/100,000, SD±6.23, CI 120.6–145) with
indications of a downward trend from 104.9/100,000 to
97.2/100,000 in the second period. Then came malignant
neoplasms of respiratory and intrathoracic organs (C30-
C39, 63.6/100,000, SD±5.31, CI 87.8–108.6) followed by
malignant neoplasm of breast (C50, 44.3/100.000), malig-
nant neoplasms of female genital organs (C51-C58, 28.3/
100.000) and in situ neoplasms (D00-D09, 26.9/100.000).
The referring incidence rates fell between the two three-
-year periods. Comparing the data in the two periods,
malignant neoplasms of urinary tract (C64-C68, 25/
100,000), melanoma and other malignant neoplasms of
skin (C43-C44, 24/100,000), C60-C63 (23/100,000) and
malignant neoplasms, stated or presumed to be primary,
of lymphoid, haematopoietic and related tissue (C81-
C96, 19.3/100,000) reflected an upward trend. Other
groups of cancer disclosed a decline in the cancer inci-
dence rates. Due to the age of onset, all groups aged 65+
had the highest incidence rate, except the in situ neo-
plasm group (D00-D09, 49.7/100,000) which had the hig-
hest incidence rate at the age between 20 and 44 years.
Females had a cancer incidence rate of 370/100,000 in
the period from 2001 to 2006. The incidence rate showed
a downward trend from 391.9/100,000 in the 2001–2003
period to 348.3/100,000 in the 2004–2006 period. The
highest incidence rate among females was found with
cancer site C50 (79.3/100,000). Group C15-C26 (73.2/
100,000) was characterized by the second highest inci-
dence rate. Next, groups D00-D09 and C51-C58 with in-
cidence rates of 51.4 and 51/100,000, respectively. Out of
all 15 reference cancer groups, just four cancer groups
showed a slight increase in the incidence rates. These
were groups C43-C44 (from 17.7 to 20/100,000), C81-C96
(from 14.8 to 15.6/100,000), malignant neoplasms of thy-
roid and other endocrine glands (C73-C75, from 12 to
13/100,000) and malignant neoplasms of mesothelial and
soft tissue (C45-C49, from 2.3 to 2.5/100,000). Female pa-
tients from cancer group D00-D09 became sick at the
highest incidence rate of 99.9/100,000 at the age 20–44
years.
Concerning males, the cancer incidence rate rose
from 484.6/100,000 in the 2001–2003 period to 503.8/
100,000 in the 2004–2006 period. Group C15-C26 was
featured by the highest incidence rate (141.6/100,000).
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TABLE 2 (continued)
Difference in years between the median age at death and at diagnosis
Females Males Both genders








C00-C14 5.9 9.3 1.2 8,08 3.3 4.9 1.6 3.34 3.5 5.4 1.4 3.99
C15-C26 2.8 3.0 2.6 0,34 2.2 2.5 1.9 0.60 2.4 2.7 2.2 0.47
C30-C39 2.3 2.5 2.0 0,53 1.5 1.7 1.3 0.44 1.6 1.8 1.4 0.47
C40-C41 15.1 10.5 22.9 –12,36 7.9 3.2 11.5 –8.27 10.6 7.3 14.8 –7.46
C43-C44 5.9 7.2 4.2 3,04 5.5 7.0 4.2 2.78 5.4 6.9 3.9 3.03
C45-C49 8.8 7.4 10.1 –2,66 9.1 11.9 4.5 7.46 9.1 9.9 8.5 1.42
C50 7.5 7.1 8.2 –1,10 5.9 5.6 5.6 –0.05 26.3 27.7 24.9 2.89
C51-C58 7.4 8.2 6.5 1,63 – – – – 7.4 8.2 6.5 1.63
C60-C63 – – – – 7.2 7.4 7.0 0.36 7.2 7.4 7.0 0.36
C64-C68 6.2 5.6 7.0 –1,40 5.7 5.3 6.3 –0.94 5.9 5.4 6.5 –1.05
C69-C72 9.1 10.9 7.0 3,94 4.6 5.4 3.7 1.77 6.8 8.2 5.2 3.00
C73-C75 16.1 18.5 13.1 5,43 14.6 11.7 22.6 –10.90 15.0 14.6 15.0 –0.39
C76-C80 4.7 4.9 4.3 0,60 2.8 4.5 0.4 4.02 3.5 4.7 1.9 2.73
C81-C96 6.5 6.3 6.9 –0,65 7.6 7.3 7.9 –0.60 7.2 6.8 7.5 –0.67
D37-D48 21.4 21.3 23.5 –2,22 20.7 18.3 23.9 –5.66 21.0 20.0 23.4 –3.43
C00-D48 9.3 9.7 8.9 0,78 3.6 4.0 3.2 0.77 6.2 6.7 5.7 0.98
Difference (in years) = period II (2004–2006) – period I (2001–2003)
Group C30-C39 immediately followed group C15-C26
(the incidence rate of 124.9/100,000). Both of these lead-
ing cancer groups revealed a slight decline from the first
to the second period. Out of 15 cancer groups, the inci-
dence rate increased in seven groups (C60-C63, C64-C68,
C81-C96, D37-D48, C40-C41, D00-D09 and C50). A par-
ticularly large increase referred to group C60-C63 (from
45.9 to 70.1/100,000). With respect to six cancer groups,
the incidence rate decline (C15-C26, C30-C39, C00-C14,
C69-C72, C76-C80, C45-C49 and C73-C75) whereas the
incidence rate remained the same in group C81-C96.
The total cancer mortality rate in the OBC in the
6-year period was 240.7/100,000 (SD±7.8, CI 225.4–256)
(Table 4, Figure 3). It decline from 256.1/100,000 in the
2001–2003 period (SD±8.04, CI 240.3–271.8) to 225.3/
100,000 in 2004–2006 period (SD±7.54, CI 210.5–240.1).
Group C15-C26 was characterized by the highest mortal-
ity rate among both genders (80/100,000). This type of
cancer was also the most common cause of death in both
genders (in females 56.8/100,000 and in males 114/
100,000, respectively). Group C15-C26 followed by groups
C30-C39 and C50 (56.2 and 17.9/100,000, respectively).
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Fig. 2. The cancer age-standardized incidence rate for C00-D48
in the period 2001-2006 in the OBE per 100,000 inhabitants us-
ing the EU standard population. The downward trendline in fe-
males suggest that a strong relationship exists between age-stan-
dardized incidence rate and years, R2=0.606 (R2>0.48<0.81)
and weak rising trendline relationship in males (R2 =0.150,
(R2>0.04<0.16)).
TABLE 3
THE CANCER AGE-STANDARDIZED INCIDENCE RATE FOR C00-D48 IN TWO PERIODS (BY AGE GROUPS AND GENDERS)
IN THE OBC PER 100,000 INHABITANS USING THE EU STANDARD POPULATION
Age-standardized incidence rate – Females
0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C50 – – – 28.4 23.2 25.8 183.0 168.1 175.6 249.0 229.9 239.5 83.1 75.4 79.3
C15-C26 0.8 – 0.4 11.6 7.5 9.6 97.8 90.7 94.2 441.9 398.4 420.1 77.3 69.1 73.2
D00-D09 – 0.8 0.4 115.8 84.0 99.9 64.1 50.8 57.5 17.0 19.1 18.0 58.4 44.4 51.4
C51-C58 0.8 1.7 1.3 28.4 24.9 26.6 97.0 88.4 92.7 180.1 149.4 164.8 54.2 47.7 51.0
C30-C39 – – – 5.8 2.3 4.1 33.6 34.4 34.0 98.5 74.2 86.4 21.3 17.6 19.4
C43-C44 – – – 2.3 1.2 1.7 26.6 25.8 26.2 93.2 119.7 106.5 17.7 20.0 18.9
D37-D48 7.6 4.2 5.9 10.4 9.3 9.8 34.4 25.0 29.7 39.2 28.6 33.9 18.8 13.9 16.3
C81-C96 1.7 1.7 1.7 5.2 3.5 4.3 19.6 23.5 21.5 68.9 73.1 71.0 14.8 15.6 15.2
C64-C68 – 0.8 0.4 2.3 1.7 2.0 16.4 21.1 18.8 64.6 62.5 63.6 12.0 13.0 12.5
C73-C75 – – – 9.8 14.5 12.2 22.7 25.0 23.9 12.7 8.5 10.6 10.5 12.3 11.4
C69-C72 6.7 5.0 5.9 5.2 2.9 4.1 14.1 14.1 14.1 22.3 19.1 20.7 9.7 8.1 8.9
C76-C80 0.8 – 0.4 1.2 1.2 1.2 7.0 7.8 7.4 37.1 24.4 30.7 6.5 5.0 5.8
C00-C14 – – – 1.7 – 0.9 4.7 4.7 4.7 12.7 11.7 12.2 3.2 2.5 2.8
C45-C49 0.8 0.8 0.8 – 1.2 0.6 4.7 2.3 3.5 8.5 11.7 10.1 2.3 2.5 2.4
C40-C41 1.7 0.8 1.3 1.2 1.2 1.2 3.1 0.8 2.0 3.2 2.1 2.6 2.0 1.1 1.6
C00-D48 21.0 16.0 18.5 229.3 178.3 203.8 628.7 582.6 605.7 1348.9 1232.3 1290.6 391.9 348.3 370.1
Years of data collection: I period – 2001–2003, II period – 2004–2006, T – period 2001–2006
Fig. 3. The cancer age-standardized mortality rate for C00-D48
in the period 2001-2006 in the OBE per 100,000 inhabitants us-
ing the EU standard population. The downward trendline in fe-
males suggest that a very strong and extremely dependable rela-
tionship exists between age-standardized mortality rate and
years, R2=0.887 (R2>0.80) and moderate downward trendline
relationship in males (R2 =0.225, (R2>0.16<0.49)).
Both the total and gender-based cancer mortality rate
declined in all groups, except in males groups C30- C39
(from 112 to 112.8/100,000) and C60-C63 (from 28.9 to
31.8/100,000) which showed a rise in the mortality rate.
The patients with cancer in the OBC had 40.1%
age-adjusted 5-year relative survival estimates for 2001–
2006 (Table 5, Figure 4). The lowest survival rate (14.8%)
was related to the patients with cancer C30-C39, fol-
lowed by patients with C76-C80 (16.6%), and then by pa-
tients with C15-C26 (23.6%). The 5-year relative survival
from cancer for males was 32.4% which was a signifi-
cantly lower than the corresponding females rate (48.8%).




0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C15-C26 – 0.8 0.4 13.1 10.8 12.0 200.3 179.5 189.9 818.3 814.6 816.5 144.7 138.5 141.6
C30-C39 0.8 – 0.4 9.1 8.0 8.6 232.0 208.7 220.4 600.7 611.9 606.3 127.5 122.3 124.9
C60-C63 0.8 0.8 0.8 9.7 13.7 11.7 29.2 44.2 36.7 318.0 491.0 404.5 45.9 70.1 58.0
C64-C68 – 0.8 0.4 2.3 5.1 3.7 65.9 60.1 63.0 223.2 247.4 235.3 41.8 44.3 43.0
C43-C44 1.6 – 0.8 5.7 2.9 4.3 27.5 49.2 38.4 152.5 215.7 184.1 26.1 37.0 31.6
C00-C14 – – – 6.3 1.1 3.7 66.8 57.6 62.2 76.3 91.1 83.7 27.3 24.8 26.0
C81-C96 4.8 4.8 4.8 9.1 9.1 9.1 26.7 34.2 30.5 119.0 107.9 113.4 24.3 25.0 24.7
D37-D48 4.0 4.8 4.4 8.0 8.0 8.0 17.5 16.7 17.1 44.6 48.4 46.5 13.2 13.7 13.5
C69-C72 3.2 0.8 2.0 4.6 6.3 5.4 20.0 15.0 17.5 29.8 31.6 30.7 10.8 9.7 10.2
C76-C80 0.8 – 0.4 4.0 0.6 2.3 15.9 9.2 12.5 48.4 46.5 47.4 10.9 7.6 9.3
C45-C49 1.6 – 0.8 1.1 1.1 1.1 4.2 3.3 3.8 18.6 13.0 15.8 3.9 2.7 3.3
C73-C75 0.8 – 0.4 3.4 3.4 3.4 3.3 2.5 2.9 11.2 5.6 8.4 3.5 2.4 3.0
C40-C41 – 1.6 0.8 – 1.7 0.9 5.0 2.5 3.8 11.2 7.4 9.3 2.5 2.5 2.5
D00-D09 1.6 – 0.8 0.6 – 0.3 0.8 4.2 2.5 3.7 11.2 7.4 1.3 2.3 1.8
C50 – – – – – – 0.8 1.7 1.3 5.6 5.6 5.6 0.8 1.0 0.9
C00-D48 19.9 14.3 17.1 77.0 71.8 74.4 716.1 688.6 702.4 2481.0 2748.8 2614.9 484.6 503.8 494.2
Both genders
0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C15-C26 0.4 0.4 0.4 12.4 9.2 10.8 147.4 133.6 140.5 578.5 549.5 564.0 104.9 97.2 101.1
C30-C39 0.4 – 0.2 7.5 5.2 6.3 129.6 118.7 124.2 280.8 269.3 275.1 66.0 61.1 63.6
C50 - – – 14.1 11.5 12.8 94.9 87.6 91.2 160.7 148.5 154.6 46.3 42.3 44.3
C51-C58 0.4 0.8 0.6 14.1 12.4 13.2 50.1 45.6 47.8 114.8 95.2 105.0 30.2 26.4 28.3
D00-D09 0.8 0.4 0.6 57.7 41.7 49.7 33.5 28.3 30.9 12.2 16.2 14.2 30.2 23.5 26.9
C64-C68 – 0.8 0.4 2.3 3.4 2.9 40.4 40.0 40.2 122.2 129.6 125.9 24.3 25.7 25.0
C43-C44 0.8 – 0.4 4.0 2.0 3.0 27.1 37.1 32.1 114.8 154.6 134.7 21.0 27.0 24.0
C60-C63 0.4 0.4 0.4 4.9 6.9 5.9 14.1 21.4 17.8 115.4 178.2 146.8 18.1 27.5 22.8
C81-C96 3.3 3.3 3.3 7.2 6.3 6.8 23.0 28.7 25.8 87.1 85.7 86.4 18.8 19.8 19.3
D37-D48 5.7 4.5 5.1 9.2 8.6 8.9 26.2 21.0 23.6 41.2 35.8 38.5 16.0 13.5 14.7
C00-C14 – – – 4.0 0.6 2.3 34.7 30.3 32.5 35.8 40.5 38.1 14.0 12.2 13.1
C69-C72 4.9 2.9 3.9 4.9 4.6 4.7 17.0 14.5 15.7 25.0 23.6 24.3 10.1 8.7 9.4
C73-C75 0.4 – 0.2 6.6 8.9 7.8 13.3 14.1 13.7 12.2 7.4 9.8 7.1 7.5 7.3
C76-C80 0.8 – 0.4 2.6 0.9 1.7 11.3 8.5 9.9 41.2 32.4 36.8 8.5 6.0 7.2
C45-C49 1.2 0.4 0.8 0.6 1.1 0.9 4.4 2.8 3.6 12.2 12.2 12.2 3.0 2.6 2.8
C40-C41 0.8 1.2 1.0 0.6 1.4 1.0 4.0 1.6 2.8 6.1 4.1 5.1 2.1 1.7 1.9
C00-D48 20.4 15.1 17.8 152.5 124.7 138.6 671.0 633.9 652.4 1759.8 1782.7 1771.3 420.6 402.6 411.6
Years of data collection: I period – 2001–2003, II period – 2004–2006, T – period 2001–2006
The age distribution at diagnosis and at deaths by
cancer group is shown in Table 6. Out of all the cases,
52.6% of patients were aged 65+. That age was abso-
lutely dominated by cancer groups C60-C63 (74.2%),
C43-C44 (67.3%) and C15-C26 (65.9%). The only cancer
site with more than half of new cases and deaths within
the 45–64 age group was C00-C14 (55.3% and 55.5%, re-
spectively). The morbidity in the 20–44 age group was
above all contributed by cancer D00-D09 (65.8%).
Patients of both genders mostly died in the age 65+
(65.4%). At that age, the mortality rate was higher among
females, although 2/3 or more of the total deaths from
cancer (females 70.3% and males 62%) were registered at
that age. The highest mortality in the oldest age group
was connected with cancer groups C60-C63 (86.7%),
D37-D48 (81%) and C43-C44 (76.8%).
Discussion
In the 2001–2006 period there were 1,589 newly diag-
nosed cancer patients a year on average in the OBC,
among which there were slightly more males (50.3%). In
the same period, a total of 968 patients died of cancer on
a yearly basis on average and again, there were more
males (58.9%) than females among them. The age-stan-
dardized incidence and mortality rates declined in both
periods and for both genders. The incidence rate in males
increased from 485/100,000 in the first period to 504/
100,000 in the second period, which could be partly ex-
plained by the lack of sufficient motivation (Table 1, Fig-
ure 2). At the time of the generation of these data, there
were no preventive programmes against cancer at the
national level, but these kinds of information were avail-
able in all media and hence it was possible to undergo a
routine examination. The situation with females was
completely different. The cancer incidence rate in the
OBC in this period was above the Croatia average (Cro-
atian average for both genders was 365/100,000, for
males 473/100,000, for females 296/100,000)20. In 2006,
the cancer incidence rate in the OBC was higher than the
equivalent rate in the EU and this count for both gen-
ders3.
The median age at cancer diagnosis in the OBC was
62.7 years. The diagnosis of cancer in the second period
shifted by 1.32 years into an older age (first period 62.1
years, and second 63.4 years of age). The cancer in fe-
males was diagnosed later 2.9 years (age 61.2 years) than
in males (age 64.1 years, Table 2, Figure 1). A similar re-
lationship between the genders in the context of the me-
dian age of cancer was revealed in some parts of the USA
where the difference in median age was greater and the
age at disease shifted by 3.3 years in an older age21,22. Ma-
lignant neoplasms of digestive organs (C15-C26), malig-
nant neoplasms of respiratory and intrathoracic organs
(C30-C39), malignant neoplasms of female genital or-
gans (C51-C58) and malignant neoplasms of male genital
organs (C60-C63) accounted for much more than half of
all cancers and at the same time, the median age at diag-
nosis exceeded 60 year23. Cancer type C15-C26 affected
patients at the latest age and that age was 67.8 years for
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TABLE 4
THE AGE-STANDARDIZED MORTALITY RATES FOR ALL CANCERS IN TWO PERIODS (BY AGE GROUPS AND GENDERS)
IN THE OBC PER 100,000 USING THE EU STANDARD POPULATION
Age-standardized mortality rate
Females
0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C15-C26 – – – 4.6 2.9 3.8 66.5 60.2 63.3 379.3 342.3 360.8 60.0 53.7 56.8
C50 – – – 10.4 2.3 6.4 61.0 41.4 51.2 164.2 120.8 142.5 37.0 24.5 30.7
C51-C58 – – – 5.2 7.5 6.4 40.7 34.4 37.5 136.7 100.7 118.7 27.0 22.3 24.7
C30-C39 – – – 3.5 1.2 2.3 26.6 28.9 27.8 86.9 65.7 76.3 17.4 14.9 16.1
C81-C96 0.8 – 0.4 1.2 1.2 1.2 12.5 8.6 10.6 56.2 53.0 54.6 10.0 8.4 9.2
C64-C68 – – – 1.2 0.6 0.9 3.9 6.3 5.1 49.8 33.9 41.9 6.9 5.5 6.2
C43-C44 – – – 1.2 0.6 0.9 4.7 7.0 5.9 49.8 29.7 39.7 7.1 5.2 6.1
C69-C72 2.5 1.7 2.1 – 1.2 0.6 10.2 7.0 8.6 18.0 14.8 16.4 5.3 4.3 4.8
C76-C80 – – – – – – 4.7 3.9 4.3 36.0 22.3 29.1 5.1 3.4 4.3
D37-D48 – – – – – – 3.1 0.8 2.0 19.1 5.3 12.2 2.9 0.8 1.8
C45-C49 – – – – – – 3.9 1.6 2.7 6.4 10.6 8.5 1.7 1.6 1.6
C00-C14 – – – – – – 3.1 3.1 3.1 9.5 5.3 7.4 1.8 1.4 1.6
C73-C75 – – – – 0.6 0.3 2.3 2.3 2.3 5.3 3.2 4.2 1.2 1.1 1.2
C40-C41 – – – 1.2 – 0.6 – 0.8 0.4 3.2 2.1 2.6 0.8 0.4 0.6
C00-D48 3.4 1.7 2.5 28.4 18.0 23.2 243.2 206.5 224.8 1020.4 809.5 915.0 184.0 147.4 165.7
Years of data collection: I – period 2001–2003, II – period 2004–2006, T – period 2001–2006
both genders. Males usually developed that type of can-
cer 3.4 years earlier then females, at the age of 66.3 years
while on average, females were diagnosed with that can-
cer at the age of 69.7 years. The average age at diagnoses
of cancer C60-C63 in males was 67.8 years. Great differ-
ences in the age of disease for groups C40-C41 in males
was consequence of a small number of patients.
The highest incidence and mortality rates in both
genders were linked with cancer groups C15-C26 (101.1
and 80/100,000, respectively) and C30-C39 (63.6 and
56.2/100,000, respectively). These groups showed a de-
clining tendency (Tables 3 and 4, Figure 2 and 3). In fe-
males, the next two places were taken by cancer types
C50 (44.3 and 19.9/100,000, respectively) and C51-C58
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TABLE 4 (continued)
THE AGE-STANDARDIZED MORTALITY RATES FOR ALL CANCERS IN TWO PERIODS (BY AGE GROUPS AND GENDERS)
IN THE OBC PER 100,000 USING THE EU STANDARD POPULATION
Males
0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C15-C26 – – – 8.6 7.4 8.0 139.4 131.0 135.2 727.2 680.7 703.9 117.8 110.2 114.0
C30-C39 – – – 5.1 5.7 5.4 197.8 187.0 192.4 552.4 582.1 567.2 112.0 112.8 112.4
C60-C63 – – – 1.1 0.6 0.9 11.7 13.4 12.5 232.5 256.7 244.6 28.9 31.8 30.3
C64-C68 – – – 1.7 1.1 1.4 30.9 18.4 24.6 161.8 148.8 155.3 26.1 21.4 23.7
C00-C14 – – – 1.1 0.6 0.9 45.9 38.4 42.2 67.0 65.1 66.0 19.2 17.0 18.1
C81-C96 – 0.8 0.4 5.1 2.9 4.0 14.2 15.0 14.6 102.3 80.0 91.1 16.6 13.8 15.2
C43-C44 0.8 – 0.4 1.7 0.6 1.1 8.3 14.2 11.3 98.6 93.0 95.8 13.8 14.0 13.9
C76-C80 – – – 1.7 0.6 1.1 13.4 8.3 10.9 48.4 44.6 46.5 9.3 7.2 8.2
C69-C72 1.6 0.8 1.2 2.9 3.4 3.1 14.2 10.9 12.5 29.8 27.9 28.8 8.3 7.2 7.7
D37-D48 – – – 0.6 – 0.3 2.5 0.8 1.7 24.2 22.3 23.2 3.5 2.7 3.1
C45-C49 – – – – 0.6 0.3 3.3 0.8 2.1 16.7 7.4 12.1 2.7 1.2 2.0
C40-C41 – 0.8 0.4 – – – 2.5 1.7 2.1 11.2 7.4 9.3 1.9 1.5 1.7
C73-C75 0.8 – 0.4 – – – 1.7 0.8 1.3 9.3 1.9 5.6 1.7 0.4 1.0
C50 – – – – – – – 0.8 0.4 5.6 3.7 4.6 0.6 0.6 0.6
C00-D48 3.2 2.4 2.8 29.6 23.4 26.5 485.8 441.5 463.7 2086.7 2021.6 2054.2 362.3 341.6 352.0
Both genders
0–19 20–44 45–64 65+ All ages
ICD-10 I II T I II T I II T I II T I II T
C15-C26 – – – 6.6 5.2 5.9 101.7 94.5 98.1 505.6 465.1 485.3 83.4 76.6 80.0
C30-C39 – – – 4.3 3.4 3.9 109.4 105.4 107.4 255.8 253.1 254.5 57.0 55.4 56.2
C50 – – – 5.2 1.1 3.2 31.5 21.8 26.6 106.7 78.3 92.5 21.4 14.5 17.9
C51-C58 – – – 2.6 3.7 3.2 21.0 17.8 19.4 87.1 64.1 75.6 15.7 12.8 14.3
C64-C68 – – – 1.4 0.9 1.1 17.0 12.1 14.5 90.5 75.6 83.0 14.7 11.6 13.2
C81-C96 0.4 0.4 0.4 3.2 2.0 2.6 13.3 11.7 12.5 72.9 62.8 67.8 12.6 10.7 11.6
C60-C63 – – – 0.6 0.3 0.4 5.7 6.5 6.1 84.4 93.2 88.8 10.9 12.0 11.4
C43-C44 0.4 – 0.2 1.4 0.6 1.0 6.5 10.5 8.5 67.5 52.7 60.1 9.7 8.6 9.1
C00-C14 – – – 0.6 0.3 0.4 23.8 20.2 22.0 30.4 27.0 28.7 9.5 8.1 8.8
C69-C72 2.0 1.2 1.6 1.4 2.3 1.9 12.1 8.9 10.5 22.3 19.6 20.9 6.6 5.5 6.1
C76-C80 – – – 0.9 0.3 0.6 8.9 6.1 7.5 40.5 30.4 35.4 7.0 5.0 6.0
D37-D48 – – – 0.3 – 0.1 2.8 0.8 1.8 20.9 11.5 16.2 3.1 1.5 2.3
C45-C49 – – – – 0.3 0.1 3.6 1.2 2.4 10.1 9.5 9.8 2.0 1.4 1.7
C73-C75 0.4 – 0.2 – 0.3 0.1 2.0 1.6 1.8 6.8 2.7 4.7 1.4 0.8 1.1
C40-C41 – 0.4 0.2 0.6 – 0.3 1.2 1.2 1.2 6.1 4.1 5.1 1.2 0.9 1.0
C00-D48 3.3 2.0 2.7 29.0 20.7 24.8 360.5 320.2 340.4 1407.4 1249.5 1328.4 256.1 225.3 240.7
Years of data collection: I – period 2001–2003, II – period 2004–2006, T – period 2001–2006
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TABLE 5
THE PERCENTAGE OF OVERALL AGE-STANDARDIZED 5-YEAR RELATIVE SURVIVAL RATES FOR ALL CANCERS (BOTH GENDERS)
IN THE OBC IN THE 2001–2005 PERIOD
Females – % (number of survival cases)
ICD-10 0–19 20–44 45–64 65+ All ages
C00–C14 – – 100.1 (3) 33.7 (3) 53.3 (9) 50.6 (15)
C15-C26 100.1 (1) 60.7 (20) 37.6 (80) 18.7 (113) 24.3 (214)
C30-C39 – – 46.7 (7) 22.8 (16) 15.8 (20) 19.7 (43)
C40-C41 100.1 (2) 0.0 – 101.0 (4) 0.0 – 50.6 (6)
C43-C44 – – 40.0 (2) 85.3 (49) 74.5 (116) 73.9 (167)
C45-C49 100.1 (1) 100.1 (2) 33.7 (3) 20.0 (3) 32.6 (9)
C50 – – 76.8 (66) 76.4 (304) 49.9 (171) 64.2 (541)
C51-C58 100.1 (4) 80.6 (62) 67.2 (137) 37.1 (89) 54.5 (292)
C60-C63 – – – – – – – – – –
C64-C68 – – 71.5 (5) 80.4 (35) 36.7 (32) 50.6 (72)
C69-C72 64.3 (9) 84.7 (11) 42.9 (14) 33.3 (10) 48.4 (44)
C73-C75 – – 100.1 (31) 92.9 (46) 66.6 (10) 90.8 (87)
C76-C80 100.1 (1) 75.1 (3) 47.5 (8) 8.5 (4) 22.5 (16)
C81-C96 75.1 (3) 69.3 (9) 45.4 (22) 27.7 (27) 36.3 (61)
D37-D48 100.1 (13) 100.1 (34) 94.4 (57) 75.6 (39) 88.9 (143)
C00-D48 85.1 (34) 78.6 (255) 64.0 (778) 35.1 (643) 48.8 (1710)
Males – % (number of survival cases)
ICD-10 0–19 20–44 45–64 65+ All ages
C00–C14 100.1 (1) 76.6 (13) 35.6 (43) 26.3 (18) 35.7 (75)
C15-C26 100.1 (1) 38.5 (15) 35.0 (146) 15.6 (102) 23.1 (264)
C30-C39 100.1 (1) 30.8 (12) 17.1 (79) 9.8 (48) 13.7 (140)
C40-C41 50.0 (1) 66.7 (2) 50.5 (3) 0.0 – 30.4 (6)
C43-C44 50.0 (1) 66.7 (10) 70.3 (48) 62.2 (91) 62.8 (150)
C45-C49 100.1 (2) 100.1 (3) 44.9 (4) 24.6 (3) 45.0 (12)
C50 – – – – 101.0 (2) 21.3 (1) 43.4 (3)
C51-C58 – – – – – – – – – –
C60-C63 100.1 (2) 97.4 (36) 67.0 (59) 47.2 (155) 53.4 (252)
C64-C68 100.1 (1) 58.4 (7) 62.0 (81) 44.8 (79) 51.1 (168)
C69-C72 60.0 (3) 43.8 (7) 38.2 (14) 7.6 (2) 30.6 (26)
C73-C75 100.1 (1) 100.1 (9) 50.5 (3) 45.7 (3) 70.5 (16)
C76-C80 100.1 (1) 50.1 (5) 8.8 (2) 2.3 (1) 11.3 (9)
C81-C96 91.0 (10) 59.3 (16) 53.7 (34) 18.1 (17) 38.6 (77)
D37-D48 100.1 (10) 95.6 (21) 88.0 (27) 60.1 (22) 79.4 (80)
C00-D48 87.6 (35) 62.7 (156) 37.2 (545) 25.9 (542) 32.3 (1278)
Both genders – % (number of survival cases)
ICD-10 0–19 20–44 45–64 65+ All ages
C00-C14 100.1 (1) 80.1 (16) 35.5 (46) 31.6 (27) 37.5 (90)
C15-C26 100.1 (2) 48.7 (35) 35.9 (226) 17.1 (215) 23.6 (478)
C30-C39 100.1 (1) 35.2 (19) 17.8 (95) 11.0 (68) 14.8 (183)
C40-C41 75.1 (3) 40.0 (2) 70.7 (7) 0.0 – 38.0 (12)
C43-C44 50.0 (1) 60.1 (12) 77.2 (97) 68.5 (207) 68.2 (317)
C45-C49 100.1 (3) 100.1 (5) 39.3 (7) 22.1 (6) 38.7 (21)
C50 – – 76.8 (66) 76.5 (306) 49.6 (172) 64.1 (544)
C51-C58 100.1 (4) 80.6 (62) 67.2 (137) 37.1 (89) 54.5 (292)
C60-C63 100.1 (2) 97.4 (36) 67.0 (59) 47.2 (155) 53.4 (252)
C64-C68 100.1 (1) 63.2 (12) 66.6 (116) 42.1 (111) 51.0 (240)
C69-C72 63.2 (12) 62.1 (18) 40.4 (28) 21.3 (12) 39.8 (70)
C73-C75 100.1 (1) 100.1 (40) 88.4 (49) 60.3 (13) 86.9 (103)
C76-C80 100.1 (2) 57.2 (8) 25.3 (10) 5.5 (5) 16.6 (25)
C81-C96 86.7 (13) 62.6 (25) 50.1 (56) 23.0 (44) 37.6 (138)
D37-D48 100.1 (23) 98.3 (55) 92.2 (84) 69.2 (61) 85.2 (223)
C00-D48 86.3 (69) 71.7 (411) 49.4 (1323) 30.2 (1185) 40.1 (2988)
– »–« – no cases, 0.0 – no survival cases
(28.3 and 14.3/100,000, respectively). If cancer C50 and
cancer of female genital organs (C51-C58) are observed
jointly, then these two cancer groups together occupied
the second position (C50 in males is diagnosed only in a
few cases). The same two cancer groups together had sig-
nificantly lower mortality rates than that in group C30-
C29 (the second place pursuant to the mortality rate),
which represents a big difference from their ratio accord-
ing to the incidence rate.
The leading cancer groups in females were C50 and
C15-C26, which showed a downward trend in the two pe-
riods (Table 3, Figure 2). The trend was perhaps the re-
sult of female’s greater concern for their health but also
of the progress of medicine in the field of diagnostics and
treatment of leading female’s cancers. Public prevention
programmes at the Croatian level were first initiated in
2006. The first one was the breast cancer prevention
programme. The second one was the colorectal cancer
programme which was initiated in 2007. Compared with
the data of the Croatian Cancer Registry, the incidence
rate of cancer C50 in the OBC was lower than the respec-
tive rate at the national level while the mortality rate is
slightly higher than the Croatian average. These data
can lead to the conclusion that the level of concern about
the cancer in females in the OBC is somewhat lower than
the appertaining level in Croatia as a whole, and one
needs to find an explanation for this assumption20. The
cancer incidence rate on several Croatian islands was sig-
nificantly lower in males compared to males in the OBC,
and slightly higher in females compared to females in the
OBC24. In relation to the mortality rate from C50 in the
EU, females in the OBC were in a less favourable posi-
tion than females in Croatia in general25,26.
The cancer incidence rate in young people aged 20–44
was significantly higher in females than in males (203.8
and 74.4/100,000, respectively) considering cancer groups
C50 and in situ neoplasms (D00-D09). These groups rep-
resented the most common types of cancer at that age.
However, there was slight difference in the mortality rate
at this age (23.2/100,000 in females and 24.8/100,000 in
males). The data were similar to those originating from
other European countries27. The incidence and mortality
rate in the population 65+ of age were more than twice
higher in males (2,614.9 and 2,054.2/100,000, respec-
tively) than in females (1,290.6 and 915/100,000, respec-
tively). The reason for this discrepancy can be found in
cancers that dominated the male population at that age
(cancer of the digestive system, respiratory system and
males genital organs). Other reasons also encompass a
late diagnosis, less successful treatment compared to the
leading groups of cancer in females and possible absence
of optimal health care for themselves. Preventive pro-
grammes against smoking and alcohol consumption,
early detection and good nutrition can have only the
long-term impact on the cancer incidence and mortality
in males4.
References rarely include data on the relative survival
rate for particular ICD-10 cancer groups. Authors mostly
describe single and most common cancer sites.
In the OBC 40.1% of cancer patients in the observed
period survived for five years in the period from 2001 to
2005 (Table 5, Figure 4). In the USA, 66% of cancer pa-
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TABLE 6
THE AGE DISTRIBUTION OF CANCER PACIENTS AT DIAGNOSIS AND AT DEATH BY ICD-10 GROUPS
(PERIOD 2001–2006, BOTH GENDERS)
Age distribution (%) at death Frequency
(number of cases)
Frequency
(%)Females Males Both genders
ICD-10 0–19 20–44 45–65 65+ 0–19 20–44 45–65 65+ 0–19 20–44 45–65 65+ F M T F M T
C15-C26 – 1.6 20.0 78.4 – 2.9 31.4 65.7 – 2.3 26.4 71.2 856 1109 1965 35.8 32.4 33.8
C30-C39 – 4.0 33.2 62.8 – 2.8 44.6 52.6 – 3.0 42.7 54.3 223 1090 1313 9.3 31.9 22.6
C50 – 6.4 33.2 60.4 – – 16.7 83.3 – 6.3 32.9 60.7 422 6 428 17.7 0.2 7.4
C51-C58 – 7.3 30.1 62.6 – – – – – 7.3 30.1 62.6 342 – 342 14.3 – 5.9
C64-C68 – 3.2 13.7 83.2 – 2.2 29.0 68.8 – 2.5 24.5 73.0 95 231 326 4.0 6.8 5.6
C60-C63 – – – – – 1.0 12.2 86.8 – 1.0 12.2 86.8 – 296 296 – 8.7 5.1
C81-C96 0.7 3.0 23.7 72.6 0.7 9.5 25.7 64.2 0.7 6.4 24.7 68.2 135 148 283 5.7 4.3 4.9
C43-C44 – 3.2 16.1 80.6 0.7 3.7 21.5 74.1 0.4 3.5 19.3 76.8 93 135 228 3.9 3.9 3.9
C00-C14 – – 36.4 63.6 – 2.9 57.7 39.4 – 2.5 55.3 42.1 22 175 197 0.9 5.1 3.4
C76-C80 – 1.5 19.7 78.8 – 6.3 33.8 60.0 – 4.1 27.4 68.5 66 80 146 2.8 2.3 2.5
C69-C72 8.3 3.3 38.3 50.0 4.0 14.7 40.0 41.3 5.9 9.6 39.3 45.2 60 75 135 2.5 2.2 2.3
D37-D48 – – 21.4 78.6 – 3.3 13.3 83.3 – 1.7 17.2 81.0 28 30 58 1.2 0.9 1.0
C45-C49 – – 30.4 69.6 – 5.3 31.6 63.2 – 2.4 31.0 66.7 23 19 42 1.0 0.6 0.7
C73-C75 – 6.7 40.0 53.3 10.0 – 30.0 60.0 4.0 4.0 36.0 56.0 15 10 25 0.6 0.3 0.4
C40-C41 – 25.0 12.5 62.5 6.3 6.3 25.0 62.5 4.2 12.5 20.8 62.5 8 16 24 0.3 0.5 0.4
C00-D48 0.3 3.8 25.6 70.3 0.2 3.3 34.5 62.0 0.2 3.5 30.9 65.4 2388 3420 5808 41.1 58.9 100.0
tients survived for five years after the cancer diagnosis in
the period from 1996 to 2004. This (USA data) counts
only for certain (selected) cancer sites. It should be noted
that the health care system in Croatia provides every cit-
izen with the highest possible level of healthcare avail-
able in Croatia. In the USA, the above data refer only to
those people who had adequate medical insurance, so
these data and their representativeness can be ques-
tioned. In the OBC, an apparent significant difference in
the 5-year relative survival rate between males (32.4%)
and females (48.8%) was detected. Compared to the OBC,
in Germany was significant longer 5-year relative sur-
vival rate and smaller difference between the cancer pa-
tients by gender, where the ratio of survival was similar
in favour of females, but with a significantly smaller dif-
ference between males and females28. The 5-year relative
survival rate in females in the EU was slightly higher
than in the OBC (51,2% and 48.8%, respectively), while
the situation with males was adverse (39,8% and 32.4%,
respectively)29.
The age distribution of cancer patients by gender in
the OBC was not significantly different from the age dis-
tribution of cancer patients in the USA30,31. Patients be-
low 20 years of age on the OBC represented 1% of all pa-
tients, and their mortality was five times lower (0,2%).
Greater differences from the average mortality rate for
that age group were found with cancer group of malig-
nant neoplasms of eye, brain and other parts of central
nervous system (C69-C72, 5.9%), malignant neoplasms
of thyroid and other endocrine glands (C73-C75, 4.2%)
and malignant neoplasms of mesothelial and soft tissue
(C45-C49, 4%). The differences resulted from a small
number of patients belonging to that age group. Cancer
patients aged 65+ made up 52.6% of all cancer patients
and constituted more than 2/3 of deaths (65.4%).
On the basis of these data, it could be concluded that
the concern about cancer patients in the OBC has not
reached the Croatian level yet, and is far below the Euro-
pean one despite the human and technical capacity avail-
able in the OBC. This assertion is mostly supported by
the data on 5-year relative survival.
Limitations
Patients who were treated outside the public hospital
in the OBC are not registered in IPHO. Despite the ef-
forts to obtain this information (they exist at the na-
tional level) in their original form, the authors were un-
able to obtain that data for unknown reasons. Therefore,
the data of cancer in the OBC may differ from data of
cancer for the OBC at the state level.
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RAK (C00-C48) U OSJE^KO-BARANJSKOJ @UPANIJI, HRVATSKA
S A @ E T A K
Zavod za javno zdravstvo Osje~ko-Baranjske `upanije (OBC) je obradio podatke o oboljelima od raka koji su pri-
kupljeni iz obvezatnih statisti~kih prijava zdravstvenih ustanova `upanije, `upanijskog statisti~kog ureda i `upanijske
matice umrlih. Kori{tena je Me|unarodna klasifikacija bolesti – 10-ta revizija (ICD-10) za definiranje skupina raka,
neoplazme (C00-C97), karcinomi in situ (D00-D09) i novotvorine nesigurne ili nepoznate prirode (D37-D48). Cilj ~lanka
je prikazati veli~inu problema raka u OBC koriste}i se grupama raka iz ICD-10. Incidencija i mortalitet su izra~unati za
sve skupine raka za vremensko razdoblje 2001–2006 godine prema spolu i dobnim skupinama 0–19, 20–44, 45–64, 65+
u trenutku prvog postavljanja dijagnoze raka. Prosje~na dob u trenutku prvog postavljanja dijagnoze raka je 62,7 go-
dina, u `ena 61,2 godine, a u mu{karaca 64.1 godina. Prosje~no godi{nje oboli 411,6/100,000 (EU dobno standardizirana
stopa), a umre 240,7/100,000 stanovnika OBC. Incidencija je u oba spola najvi{a za grupe raka probavnog sustava
(C15-C26), di{ne i intratorakalne organe (C30-C39) i dojku (C50) (101,1, 63,6 i 44,3/100,000). Prve dvije grupe raka u
oba spola su i vode}e grupe u mu{karaca (141.6 i 124,9/100,000), a na tre}em je mjestu rak mu{kih spolnih organa
(C60-C63) (58/100,000). U `ena je vode}a grupa raka C50 (79,3/100,000), a zatim slijede C15-C26 (73,2/100,000) i kar-
cinom in situ (D00-D09) (51,4/100,000). Smjer i izgled stope smrtnosti u cijelosti prati stopu incidencije, ali na ni`oj
razini. Izuzetak je stopa smrtnosti u `ena gdje je vode}a grupa raka C15-C26 (56,8/100,000). Prosje~no 5-godi{nje pre-
`ivljavanje za vremensko razdoblje 2001–2005 godine je 40,1% za sva sijela u oba spola, u `ena 48,8 i 32,4% u mu{ka-
raca. 52,6% oboljelih od raka obole u dobi 65+ godina, a 65,4% umiru u istoj dobi. Ovi osnovni parametri ukazuju da se
u OBC moraju ulo`iti napori u kreiranju dugoro~ne strategije prevencije raka i ranijoj dijagnostici s ciljem produljenja
`ivotnog vijeka i podizanja kvalitete `ivota oboljelih od raka te podi}i udio 5-godi{njeg pre`ivljavanja.
J. Milas et al.: Neoplasms in Osijek-Baranja County, Coll. Antropol. 37 (2013) 4: 1209–1222
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